🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 42 of 55

  1. Retifanlimab (INCMGA00012), HOLOXAN 2000 mg, poudre pour usage parentéral, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  2. Revlimid 25 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 20 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Zelvina 5 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Imnovid 4 mg hard capsules, DIPHENHYDRAMINE , Revlimid 15 mg hard capsules, MONTELUKAST , JAMP Pomalidomide, PARACETAMOL , Revlimid 20 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Revlimid 25 mg hard cap

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  3. Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE

    Pari Pharma GmbH

    PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION

    phase 2 small molecule active

    1 trial

  4. Revumenib

    Syndax Pharmaceuticals

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  5. Revumenib

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    2 trials

  6. Revumenib

    Syndax Pharmaceuticals

    Leukemia

    phase 2 small molecule active

    1 trial

  7. Revumenib, Revumenib, SNDX-5613, Revumenib, Revumenib, SNDX-5613

    Syndax Pharmaceuticals

    Relapsed or Refractory Acute Leukemias

    phase 2 small molecule active

    1 trial

  8. Rezvilutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone-Sensitive Prostate Cancer

    phase 2 small molecule active

    1 trial

  9. Rezvilutamide

    Nanjing Zenshine Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  10. Rilvegostomig, Rilvegostomig

    AstraZeneca AB

    Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).

    phase 2 small molecule active

    1 trial

  11. Ritonavir

    Abbott Australasia Pty Ltd

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

  12. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  13. Rituximab

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 2 mab active

    1 trial

  14. Rituximab Paclitaxel Ruxolitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  15. RoActemra 20 mg/mL concentrate for solution for infusion, CD19 4-1 BBL, Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)

    phase 2 small molecule active

    1 trial

  16. RoActemra 20 mg/mL concentrate for solution for infusion, Glofitamab

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  17. Roginolisib

    United Therapeutics Europe Ltd

    Leukemia

    phase 2 small molecule active

    1 trial

  18. Romidepsin

    Takeda

    Lymphoma, T-Cell, Peripheral

    phase 2 small molecule terminated

    1 trial

  19. Romidepsin

    Fondazione Telethon ETS

    Anaplastic Large T-cell Lymphoma ALK negative, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell lymphoma, NOS

    phase 2 small molecule active

    1 trial

  20. Rozlytrek 200 mg hard capsules

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    phase 2 small molecule active

    1 trial

  21. Rozlytrek, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  22. Rubraca 300 mg film-coated tablets, Rubraca 200 mg film-coated tablets, BEVACIZUMAB, Rubraca 250 mg film-coated tablets, CARBOPLATIN, PACLITAXEL

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 small molecule active

    1 trial

  23. Rucaparib

    United Therapeutics Europe Ltd

    Cervical Cancer

    phase 2 small molecule terminated

    1 trial

  24. Rydapt 25 mg soft capsules, Dacogen 50 mg powder for concentrate for solution for infusion., Rydapt 25 mg soft capsules

    Wuhan Createrna Science and Technology Co., Ltd

    Acute myeloid leukemia, Myelodysplastic syndrome

    phase 2 small molecule active

    1 trial

  25. S-1

    United Therapeutics Europe Ltd

    Locally Advanced or Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  26. S-1

    United Therapeutics Europe Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    2 trials

  27. S095018

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  28. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  29. S095035

    Tango Therapeutics

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  30. S1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  31. S95012 concentrate solution for infusion 400mg/ 16 ml, Gazyvaro 1,000 mg concentrate for solution for infusion.

    The George Institute

    Soild Tumors

    phase 2 small molecule active

    1 trial

  32. SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK

    The George Institute

    Early triple-negative breast cancer (TNBC)

    phase 2 other active

    1 trial

  33. SAR439859, Verzenios 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, Verzenios 150 mg film-coated tablets, IBRANCE 75 mg hard capsules, Verzenios 50 mg film-coated tablets, IBRANCE 100 mg hard capsules

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  34. SAR444881

    Regeneron UK Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  35. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus Therapeutics Holdings

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial

  36. SCB01A

    Biotech Pharmaceutical Co.,

    Head and Neck Neoplasms

    phase 2 small molecule terminated

    1 trial

  37. SDREGN2810

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  38. SDX-105

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  39. SELPERCATINIB, SELPERCATINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

    phase 2 small molecule active

    1 trial

  40. SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  41. SELUMETINIB, CASODEX 50 mg compresse rivestite con film, OLAPARIB

    Istituto Gentili S.r.l.

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  42. SG+I

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC, Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  43. SHR-1210

    Hospital Authority, Hong Kong

    Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  44. SHR-1210

    The First People's Hospital of Lianyungang

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  45. SHR-1701

    The First People's Hospital of Lianyungang

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  46. SHR-1701 Combined With Fluazopalil

    Hunan Province Tumor Hospital

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  47. SHR2554/AZA + Overlapped TBF

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 other active

    1 trial

  48. SI-B001

    Sichuan Baili Pharmaceutical Co.,

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.